Galectin-1 links tumor hypoxia and radiotherapy

Area of Science:

• Oncology
• Radiation Oncology
• Cancer Biology

Background:

• Radiotherapy is a cornerstone treatment for solid tumors, crucial in both definitive and adjuvant settings.
• Achieving local tumor control with radiotherapy is often limited by factors such as tumor hypoxia, DNA damage repair mechanisms, and the host's antitumor immune response.
• Previous strategies to enhance tumor radiosensitivity by targeting these limiting factors have shown restricted success.

Purpose of the Study:

• To investigate the role of galectin-1 (Gal-1) in protecting tumor and endothelial cells from radiation-induced damage.
• To explore the potential of targeting Gal-1 in combination with radiotherapy as a strategy to improve treatment outcomes.

Main Methods:

• This study focuses on the molecular mechanisms by which galectin-1 confers protection against radiation.
• The research investigates the interplay between Gal-1 expression, tumor microenvironment factors (hypoxia), DNA repair, and immune response in the context of radiotherapy.

Main Results:

• Evidence suggests that both tumor cells and endothelial cells employ galectin-1 (Gal-1) as a protective mechanism against radiation therapy.
• Gal-1 appears to mediate protection through multiple pathways, potentially influencing DNA repair and cellular survival post-irradiation.

Conclusions:

• Galectin-1 (Gal-1) is implicated as a key factor in tumor radioresistance.
• Targeting galectin-1 in conjunction with radiotherapy presents a promising therapeutic strategy to overcome established mechanisms of radiation resistance and improve local tumor control.